0
0
BARCELONA — A cornerstone of type 2 diabetes treatment for over 70 years may be a double-edged sword. New research suggests that sulfonylureas, some of the most commonly prescribed drugs for blood sugar management, may inadvertently speed up the progression of the disease by causing vital insulin-producing cells to lose their “identity.”
The study, published in the journal Diabetes, Obesity and Metabolism, reveals that while these drugs are effective at lowering blood sugar in the short term, long-term exposure may trigger a cellular identity crisis in the pancreas. This process, known as dedifferentiation, renders cells unable to produce or secrete insulin, potentially explaining why these medications often lose their effectiveness over time.
The “Identity Crisis” in the Pancreas
Type 2 diabetes is defined by a two-part failure: the body becomes resistant to insulin, and the pancreatic beta cells (the cells responsible for making insulin) slowly wear out.
For decades, scientists believed that as diabetes progressed, these beta cells simply died off. However, the research team led by Professor Eduard Montanya at the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has confirmed a more complex reality.
“Not only do beta cells die, but they also lose their functional identity,” explains Dr. Montanya. “Although they are still alive, they revert to a state in which they are unable to produce and secrete insulin effectively. It appears that sulfonylureas contribute to this loss of cell identity, increasing and enhancing their loss of function.”
How Sulfonylureas Work (and Fail)
Sulfonylureas—including common versions like glimepiride (Amaryl), glipizide (Glucotrol), and glyburide (Diabeta)—work by “squeezing” the pancreas to release more insulin. They are popular because they are inexpensive and highly effective at providing immediate glucose control.
However, many patients experience what doctors call “secondary sulfonylurea failure,” where the drug simply stops working after a few years. To understand why, Dr. Montanya’s team analyzed the effects of glibenclamide (a common sulfonylurea) on healthy human pancreatic cells.
The findings were striking:
-
Gene Suppression: Cells exposed to the drug showed a marked reduction in genes essential for insulin production.
-
Cellular Stress: The drug induced stress in the endoplasmic reticulum, a part of the cell responsible for manufacturing proteins.
-
Time-Dependency: The longer the cells were exposed to the medication, the more severe the loss of function became.
Expert Perspectives: A Shift in Treatment?
The medical community has been gradually shifting away from sulfonylureas in favor of newer drug classes, such as SGLT2 inhibitors (like Jardiance) and GLP-1 receptor agonists (like Ozempic), which do not carry the same risk of beta-cell exhaustion.
“This study provides a cellular ‘smoking gun’ for what we’ve observed clinically for years,” says Dr. Elena Richardson, an endocrinologist not involved in the study. “We know sulfonylureas can cause hypoglycemia and weight gain, but the idea that they might actually accelerate the underlying disease process by fundamentally changing the nature of beta cells is a significant concern.”
However, experts urge caution. For many patients globally, sulfonylureas remain the only affordable option.
“We must balance these biological findings with socioeconomic realities,” Dr. Richardson adds. “The goal isn’t to spark panic, but to encourage a more nuanced approach to how we choose second-line treatments after metformin.”
A Glimmer of Hope: Reversing the Damage
While the study’s findings are a warning, they also offer a potential breakthrough. Because the beta cells are not necessarily dead, but rather “forgetting” their job, the process might be reversible.
If scientists can find a way to “re-educate” these cells or shield them from the stress caused by sulfonylureas, it could lead to therapies that actually halt or reverse type 2 diabetes progression rather than just managing the symptoms.
“Knowing that some beta cells revert to a non-functional state opens a line of research of great clinical interest,” says Dr. Montanya. “Unlike cell death, the loss of identity is a potentially reversible phenomenon.”
What This Means for Patients
If you are currently taking a sulfonylurea, medical experts emphasize that you should not stop taking your medication abruptly. Uncontrolled blood sugar poses immediate and severe risks to your health, including kidney damage and cardiovascular issues.
Key Takeaways for Readers:
-
Review Your Regimen: At your next check-up, ask your doctor if your current treatment plan is still the most appropriate for your long-term beta-cell health.
-
Monitor Efficacy: If you notice your blood sugar levels rising despite taking your medication as prescribed, your medication may be losing its effectiveness.
-
Consider New Alternatives: If insurance and budget allow, discuss newer classes of medications that may offer better protection for your pancreatic function.
Statistical Context
-
Prevalence: According to the CDC, over 38 million Americans have diabetes, with 90-95% having type 2.
-
Market Share: While declining, sulfonylureas still account for a significant portion of diabetes prescriptions worldwide due to their low cost (often costing less than $10 per month).
-
Study Scale: The research utilized human pancreatic islets, providing a high level of relevance to human biology compared to previous animal-only models.
Reference Section
- https://scitechdaily.com/one-of-the-most-common-diabetes-treatments-may-be-making-the-disease-worse-study-warns/
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
